- Home
- STOK
as 11-15-2024 4:00pm EST
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | BEDFORD |
| Market Cap: | 721.4M | IPO Year: | 2019 |
| Target Price: | $21.40 | AVG Volume (30 days): | 405.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.77 - $17.58 | Next Earning Date: | 11-05-2024 |
| Revenue: | $16,742,999 | Revenue Growth: | 81.08% |
| Revenue Growth (this year): | 91.67% | Revenue Growth (next year): | 5.45% |
Stock Insider Trading Activity of Stoke Therapeutics Inc. (STOK)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ticho Barry | STOK | CHIEF MEDICAL OFFICER | Nov 1 '24 | Sell | $12.68 | 10,000 | $126,803.00 | 2,485 | |
| Ticho Barry | STOK | CHIEF MEDICAL OFFICER | Oct 1 '24 | Sell | $12.06 | 10,000 | $120,648.00 | 2,485 | |
| Skorpios Trust | STOK | 10% Owner | Sep 19 '24 | Sell | $14.05 | 1,937,500 | $27,221,875.00 | 8,906,181 | |
| Ticho Barry | STOK | CHIEF MEDICAL OFFICER | Sep 3 '24 | Sell | $15.16 | 10,000 | $149,480.76 | 2,485 |
Latest Stoke Therapeutics Inc. News
STOK Breaking Stock News: Dive into STOK Ticker-Specific Updates for Smart Investing
Zacks
9 days ago
Wall Street Analysts Believe Stoke Therapeutics (STOK) Could Rally 66.84%: Here's is How to Trade
Simply Wall St.
11 days ago
Need To Know: Analysts Are Much More Bullish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenues
Zacks
12 days ago
Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates
Business Wire
12 days ago
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
Zacks
16 days ago
Fortrea Holdings Inc. (FTRE) Reports Next Week: Wall Street Expects Earnings Growth
Zacks
19 days ago
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
TipRanks
a month ago
Stoke Therapeutics assumed with an Outperform at Leerink
Insider Monkey
a month ago
Stoke Therapeutics, Inc (STOK): Pioneering RNA Medicine for Genetic Diseases
Compare STOK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "STOK Stoke Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.